Chlamydia pneumoniae and vascular disease: An update

Ross, 1999, Atherosclerosis—an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Grayston, 2000, Background and current knowledge of Chlamydia pneumoniae and atherosclerosis, J Infect Dis, 181, S402, 10.1086/315596 Grayston, 1986, A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections, N Engl J Med, 315, 161, 10.1056/NEJM198607173150305 Saikku, 1988, Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction, Lancet, 2, 983, 10.1016/S0140-6736(88)90741-6 Sessa, 2003, Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease, J Vasc Surg, 37, 1027, 10.1067/mva.2003.200 Grayston, 1995, Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery, Circulation, 92, 3397, 10.1161/01.CIR.92.12.3397 Kuo, 1993, Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain, Arterioscler Thromb, 13, 1501, 10.1161/01.ATV.13.10.1501 Kuo, 1997, Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction, J Vasc Surg, 26, 29, 10.1016/S0741-5214(97)70143-5 Grayston, 1990, A new respiratory tract pathogen, J Infect Dis, 161, 618, 10.1093/infdis/161.4.618 Saikku, 1992, Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study, Ann Intern Med, 116, 273, 10.7326/0003-4819-116-4-273 Kuo, 1995, Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old), Proc Natl Acad Sci U S A, 92, 6911, 10.1073/pnas.92.15.6911 Kuo, 1993, Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries, J Infect Dis, 167, 841, 10.1093/infdis/167.4.841 Shi, 2002, Chlamydia pneumoniae and multiple infections in the aorta contribute to atherosclerosis, Pathol Int, 52, 755, 10.1046/j.1440-1827.2002.01422.x Ramirez, 1996, Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group, Ann Intern Med, 125, 979, 10.7326/0003-4819-125-12-199612150-00008 Beatty, 1994, Persistent chlamydiae, Microbiol Rev, 58, 686, 10.1128/MMBR.58.4.686-699.1994 Shor, 1992, Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques, S Afr Med J, 82, 158 Muhlestein, 1996, Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease, J Am Coll Cardiol, 27, 1555, 10.1016/0735-1097(96)00055-1 Arcari, 2005, Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military, Clin Infect Dis, 40, 1123, 10.1086/428730 Mayr, 1999, Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae, Circulation, 99, 1560, 10.1161/01.CIR.99.12.1560 Ciervo, 2002, Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease, Clin Diagn Lab Immunol, 9, 66 Fong, 2002, Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques, J Infect Dis, 186, 1469, 10.1086/344730 Huittinen, 2002, Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk, Arterioscler Thromb Vasc Biol, 22, 431, 10.1161/hq0302.104512 Mahdi, 2002, Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease, Circulation, 106, 1659, 10.1161/01.CIR.0000031567.10814.D8 Biasucci, 2003, Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes, Circulation, 107, 3015, 10.1161/01.CIR.0000078632.76653.6C Johnston, 2001, C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis, Stroke, 32, 2748, 10.1161/hs1201.099631 Mayr, 2000, Infections, immunity, and atherosclerosis, Circulation, 102, 833, 10.1161/01.CIR.102.8.833 LaBiche, 2001, Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque, Stroke, 32, 855, 10.1161/01.STR.32.4.855 Lindholt, 2001, Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms, J Vasc Surg, 34, 212, 10.1067/mva.2001.115816 Vammen, 2001, Antibodies against Chlamydia pneumoniae predict the need for elective surgical intervention on small abdominal aortic aneurysms, Eur J Vasc Endovasc Surg, 22, 165, 10.1053/ejvs.2001.1414 Maraha, 2004, Impact of serological methodology on assessment of the link between Chlamydia pneumoniae and vascular diseases, Clin Diagn Lab Immunol, 11, 789, 10.1128/CDLI.11.4.789-791.2004 Lindholt, 2004, Serum antibodies against Chlamydia pneumoniae outer membrane protein cross-react with the heavy chain of immunoglobulin in the wall of abdominal aortic aneurysms, Circulation, 109, 2097, 10.1161/01.CIR.0000127772.58427.7E Cheuk, 2005, Detection of C pneumoniae by polymerase chain reaction-enzyme immunoassay in abdominal aortic aneurysm walls and its association with rupture, Eur J Vasc Endovasc Surg, 29, 150, 10.1016/j.ejvs.2004.10.010 Blasi, 1996, Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms, J Clin Microbiol, 34, 2766, 10.1128/JCM.34.11.2766-2769.1996 Vammen, 2002, Immunoblotting analysis of abdominal aortic aneurysms using antibodies against Chlamydia pneumoniae recombinant MOMP, Eur J Vasc Endovasc Surg, 24, 81, 10.1053/ejvs.2002.1658 Wiesli, 2002, Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men, Circulation, 105, 2646, 10.1161/01.CIR.0000017862.08503.15 Muhlestein, 1998, Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model, Circulation, 97, 633, 10.1161/01.CIR.97.7.633 Fong, 2000, Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis, J Infect Dis, 181, S514, 10.1086/315607 Gupta, 1997, Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction, Circulation, 96, 404, 10.1161/01.CIR.96.2.404 Gurfinkel, 1997, Randomised trial of roxithromycin in non-Q-wave coronary syndromes, Lancet, 350, 404, 10.1016/S0140-6736(97)07201-2 Gurfinkel, 1999, Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study, Eur Heart J, 20, 121, 10.1053/euhj.1998.1283 Muhlestein, 2000, Randomized secondary prevention trial of azithromycin in patients with coronary artery disease, Circulation, 102, 1755, 10.1161/01.CIR.102.15.1755 Anderson, 2000, The ACADEMIC study in perspective (Azithromycin in coronary artery disease, J Infect Dis, 181, S569, 10.1086/315635 O’Connor, 2003, Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial, JAMA, 290, 1459, 10.1001/jama.290.11.1459 Grayston, 2005, Azithromycin for the secondary prevention of coronary events, N Engl J Med, 352, 1637, 10.1056/NEJMoa043526 Cannon, 2005, Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome, N Engl J Med, 352, 1646, 10.1056/NEJMoa043528 Moazed, 1998, Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse, J Infect Dis, 177, 1322, 10.1086/515280 Gieffers, 2004, Phagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature, Eur Respir J, 23, 506, 10.1183/09031936.04.00093304 Gaydos, 2000, Growth in vascular cells and cytokine production by Chlamydia pneumoniae, J Infect Dis, 181, S473, 10.1086/315612 Kaukoranta-Tolvanen, 1996, Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response, Microb Pathog, 21, 215, 10.1006/mpat.1996.0056 Fryer, 1997, Chlamydia species infect human vascular endothelial cells and induce procoagulant activity, J Investig Med, 45, 168 Moazed, 1997, Murine models of Chlamydia pneumoniae infection and atherosclerosis, J Infect Dis, 175, 883, 10.1086/513986 Dechend, 1999, Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression, Circulation, 100, 1369, 10.1161/01.CIR.100.13.1369 Maass, 2000, Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction, J Infect Dis, 181, S449, 10.1086/315610 Liuba, 2000, Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice, Circulation, 102, 1039, 10.1161/01.CIR.102.9.1039 Molestina, 1999, Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes, Infect Immun, 67, 1323, 10.1128/IAI.67.3.1323-1330.1999 Coombes, 1999, Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s), Infect Immun, 67, 2909, 10.1128/IAI.67.6.2909-2915.1999 Miller, 2000, Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation, J Surg Res, 90, 76, 10.1006/jsre.2000.5847 Summersgill, 1995, Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha, Infect Immun, 63, 2801, 10.1128/IAI.63.7.2801-2803.1995 Netea, 2000, Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells, Eur J Immunol, 30, 541, 10.1002/1521-4141(200002)30:2<541::AID-IMMU541>3.0.CO;2-X Geng, 2000, Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10, J Immunol, 164, 5522, 10.4049/jimmunol.164.10.5522 Kothe, 2000, Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae, Circulation, 101, 1760, 10.1161/01.CIR.101.15.1760 Stemme, 1994, Immune mechanisms in atherogenesis, Ann Med, 26, 141, 10.3109/07853899409147881 Halme, 1999, Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms, Eur J Clin Invest, 29, 546, 10.1046/j.1365-2362.1999.00463.x de Boer, 2000, Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae, Cardiovasc Res, 48, 402, 10.1016/S0008-6363(00)00195-4 Mosorin, 2000, Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery, Arterioscler Thromb Vasc Biol, 20, 1061, 10.1161/01.ATV.20.4.1061 Kol, 1998, Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression, Circulation, 98, 300, 10.1161/01.CIR.98.4.300 Vehmaan-Kreula, 2001, Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte- derived macrophages, Arterioscler Thromb Vasc Biol, 21, E1, 10.1161/01.ATV.21.1.e1 Kalayoglu, 1998, Induction of macrophage foam cell formation by Chlamydia pneumoniae, J Infect Dis, 177, 725, 10.1086/514241 Kalayoglu, 1998, A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide, Infect Immun, 66, 5067, 10.1128/IAI.66.11.5067-5072.1998 Kalayoglu, 1999, Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae, Microbes Infect, 1, 409, 10.1016/S1286-4579(99)80044-6 Kalayoglu, 1999, Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae, J Infect Dis, 180, 780, 10.1086/314931 Xu, 1997, Nitric oxide induces heat-shock protein 70 expression in vascular smooth muscle cells via activation of heat shock factor 1, J Clin Invest, 100, 1089, 10.1172/JCI119619 Lis, 1993, Protein traffic on the heat shock promoter, Cell, 74, 1, 10.1016/0092-8674(93)90286-Y Schett, 1997, Macrophage-lysis mediated by autoantibodies to heat shock protein 65/60, Atherosclerosis, 128, 27, 10.1016/S0021-9150(96)05975-8 Lamb, 2004, Impairment of vascular function following BCG immunisation is associated with immune responses to HSP-60 in the cholesterol-fed rabbit, Atherosclerosis, 172, 13, 10.1016/j.atherosclerosis.2003.08.031 Hu, 1999, The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae, J Clin Invest, 103, 747, 10.1172/JCI4582 Campbell, 2000, Mouse models of C pneumoniae infection and atherosclerosis, J Infect Dis, 181, S508, 10.1086/315629 Blessing, 2000, Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice, Infect Immun, 68, 4765, 10.1128/IAI.68.8.4765-4768.2000 Fong, 1997, Rabbit model for Chlamydia pneumoniae infection, J Clin Microbiol, 35, 48, 10.1128/JCM.35.1.48-52.1997 Laitinen, 1997, Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits, Infect Immun, 65, 4832, 10.1128/IAI.65.11.4832-4835.1997 Muhlestein, 2000, Chlamydia pneumoniae-induced atherosclerosis in a rabbit model, J Infect Dis, 181, S505, 10.1086/315627 Coombes, 2002, Chlamydia pneumoniae infection of endothelial cells induces transcriptional activation of platelet-derived growth factor-B, J Infect Dis, 185, 1621, 10.1086/340415 Liuba, 2003, Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs, Atherosclerosis, 167, 215, 10.1016/S0021-9150(03)00019-4 Chesebro, 2003, Nitric oxide synthase plays a role in Chlamydia pneumoniae-induced atherosclerosis, Cardiovasc Res, 60, 170, 10.1016/S0008-6363(03)00389-4 Campbell, 1995, Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues, J Infect Dis, 172, 585, 10.1093/infdis/172.2.585